StockData
Nexalin Technology, Inc. logo

Nexalin Technology, Inc. (NXL) stock

NXLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$1.38−0.01 (-0.72%)

Close on Nov 20, 2026Market cap $30.41MP/E –Yield –

Nexalin Technology operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Nexalin Technology's operating income for the twelve months ending Jun 30, 2026 was -$9.13M. For fiscal 2025 it was -$8.39M. The highest annual figure on record is -$1.83M in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$8.39M–
FY2024Dec 31, 2024-$7.75M–
FY2023Dec 31, 2023-$5.70M–
FY2022Dec 31, 2022-$1.83M–
FY2021Dec 31, 2021-$6.02M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.25M–
Q1 FY2026Mar 31, 2026-$2.12M–
Q4 FY2025Dec 31, 2025-$2.41M–
Q3 FY2025Sep 30, 2025-$2.35M–
Q2 FY2025Jun 30, 2025-$1.62M–
Q1 FY2025Mar 31, 2025-$2.01M–
Q4 FY2024Dec 31, 2024-$2.88M–
Q3 FY2024Sep 30, 2024-$2.51M–
Q2 FY2024Jun 30, 2024-$1.30M–
Q1 FY2024Mar 31, 2024-$1.07M–
Q2 FY2023Jun 30, 2023-$876.86K–
Q1 FY2023Mar 31, 2023-$779.43K–
Q4 FY2022Dec 31, 2022-$719.62K–
Q3 FY2022Sep 30, 2022-$293.19K–
Q2 FY2022Jun 30, 2022-$445.10K–
Q1 FY2022Mar 31, 2022-$375.12K–
Q4 FY2021Dec 31, 2021-$577.49K–
Q3 FY2021Sep 30, 2021-$1.80M–

More Nexalin Technology figures

See a number that looks wrong?